Acute Myeloid Leukemia (AML) Market Insights & Epidemiology
05 Aug 2021
First in ClassCollaborate
Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML)- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. The total number of incident cases of Acute Myeloid Leukemia (AML) associated in 7MM countries was 41,715 in 2020.
The Acute Myeloid Leukemia (AML) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Acute Myeloid Leukemia (AML) symptoms market size from 2018 to 2030 segmented by seven major markets.
The report also covers current Acute Myeloid Leukemia (AML) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.Acute Myeloid Leukemia (AML) Drug ChaptersThe Acute Myeloid Leukemia (AML) report's drug chapter segment encloses the detailed analysis of Acute Myeloid Leukemia (AML) early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Acute Myeloid Leukemia (AML) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.Acute Myeloid Leukemia (AML) Emerging DrugDevimistat (CPI-613): Rafael Pharmaceuticals Inc.Rafael Pharmaceutical's first-in-class clinical lead compound, CPI-613 (devimistat), targets enzymes involved in cancer cell energy metabolism and is located in the mitochondria of cancer cells. CPI-613 is being evaluated in multiple Phase I, I/II, II, and III clinical studies as a single agent and combined with standard drug therapies in patients diagnosed with advanced solid tumors or blood cancers. Enrolment is currently underway in a Phase III clinical trial in r/r AML.Crenolanib: Arog PharmaceuticalsCrenolanib besylate is an investigational inhibitor being developed by AROG Pharmaceuticals, LLC. The compound is currently being evaluated for safety and efficacy in clinical trials for various types of cancer, including AML, gastrointestinal stromal tumor (GIST), and glioma.
Crenolanib is an orally bioavailable benzimidazole that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTK) FLT3 (FMS-like Tyrosine Kinase 3), PDGFR (Platelet-Derived Growth Factor Receptor), and PDGFR. Unlike most RTK inhibitors, crenolanib is a type I mutant-specific inhibitor that preferentially binds to phosphorylated active kinases with the 'DFG in' conformation motif.Acute Myeloid Leukemia (AML) Market OutlookThe report's Acute Myeloid Leukemia (AML) market outlook helps build a detailed comprehension of the historic, current, and forecasted Acute Myeloid Leukemia (AML) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.This segment gives a thorough detail of Acute Myeloid Leukemia (AML) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to clearly view the market at first sight.
Key Topics Covered:
1 Key Insights
2 Report Introduction
3 Acute Myeloid Leukemia (AML) Market Overview at a Glance
4 Executive Summary of Acute Myeloid Leukemia (AML)
5 Disease Background and Overview
6 Epidemiology and Patient Population
7 Organizations contributing towards Acute Myeloid Leukemia (AML)
8 Case Reports
9 Patient Journey
10 Marketed Therapies
11 Emerging Therapies
12 Other Promising Therapies
13 Acute Myeloid Leukemia (AML): Seven Major Market Analysis
For more information about this report visit
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.